Animal models of human diseases play a critical role in the development of new therapeutic modalities, such as gene therapy. Implementation of any human gene therapy protocol requires experimental evidence of efficacy as defined by the metabolic, pathologic, and/or clinical correction of the disease processes. In addition it is critical that a careful assessment of toxicity is performed in at least two species of animals, one of which is usually a non-human primate. Authentic animal models provide the only valid experimental setting in which to assess these parameters. In addition, the availability of animal models greatly simplifies the development of such therapies. The University of Pennsylvania provides an outstanding environment in which to utilize animal models for the development of gene therapies. The School of Veterinary Medicine is a world class program located on the medical center camps that has a long tradition for identifying and characterizing animal models of human diseases. The Animal Models Core (AMC) builds on the strengths of existing programs to develop expertise, facilities and resources necessary for basic development of gene therapies and the rapid application of these technologies to the treatment of Ducshenne's Muscular Dystrophy (DMD). The following components of the AMC will be available to center participants; (1) Colonies of the mouse model for DMD have been established at athe University of Pennsylvania. (2) Specialized biohazard operating room suites have been renovated at the University of Pennsylvania and the Wistar Institute for use by the IHGT. These facilities, along with support personnel, will be provided to center participants.

Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Bridges, Charles R; Burkman, James M; Malekan, Ramin et al. (2002) Global cardiac-specific transgene expression using cardiopulmonary bypass with cardiac isolation. Ann Thorac Surg 73:1939-46
Croyle, M A; Chirmule, N; Zhang, Y et al. (2001) ""Stealth"" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 75:4792-801
Croyle, M A; Cheng, X; Sandhu, A et al. (2001) Development of novel formulations that enhance adenoviral-mediated gene expression in the lung in vitro and in vivo. Mol Ther 4:22-8
Zoltick, P W; Chirmule, N; Schnell, M A et al. (2001) Biology of E1-deleted adenovirus vectors in nonhuman primate muscle. J Virol 75:5222-9
Zhang, Y; Chirmule, N; Gao, G P et al. (2001) Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 3:697-707
Louboutin, J P; Rouger, K; Tinsley, J M et al. (2001) iNOS expression in dystrophinopathies can be reduced by somatic gene transfer of dystrophin or utrophin. Mol Med 7:355-64
Cordier, L; Gao, G P; Hack, A A et al. (2001) Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 12:205-15
Gao, G; Qu, G; Burnham, M S et al. (2000) Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther 11:2079-91
Chirmule, N; Xiao, W; Truneh, A et al. (2000) Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 74:2420-5
Cordier, L; Hack, A A; Scott, M O et al. (2000) Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. Mol Ther 1:119-29

Showing the most recent 10 out of 22 publications